CLINICAL TRIALS PROFILE FOR SEVITERONEL

Clinical Trials for Seviteronel

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02012920 ↗	A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer	Completed	Innocrin Pharmaceutical	Phase 2	The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).
NCT02130700 ↗	Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men with ER positive Breast Cancer.
NCT02130700 ↗	Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer	Completed	Innocrin Pharmaceutical	Phase 2	The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men with ER positive Breast Cancer.
NCT02445976 ↗	Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.	Completed	Prostate Cancer Clinical Trials Consortium	Phase 2	The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide and/or abiraterone.
NCT02445976 ↗	Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.	Completed	Prostate Cancer Foundation	Phase 2	The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide and/or abiraterone.

Clinical Trial Conditions for Seviteronel

Condition Name

Condition Name for
Intervention	Trials
Prostate Cancer	2
Triple Negative Breast Cancer	2
Castration-resistant Prostate Cancer	1
CRPC	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Triple Negative Breast Neoplasms	3
Prostatic Neoplasms	3
Breast Neoplasms	2
Breast Neoplasms, Male	1

Clinical Trial Locations for Seviteronel

Trials by Country

Trials by Country for
Location	Trials
United States	55
United Kingdom	2
Switzerland	2
Australia	1
Greece	1

Trials by US State

Trials by US State for
Location	Trials
Virginia	3
North Carolina	3
New York	3
Nebraska	3
Florida	3

Clinical Trial Progress for Seviteronel

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	4
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	4
Terminated	1
Not yet recruiting	1

Clinical Trial Sponsors for Seviteronel

Sponsor Name

Sponsor Name for
Sponsor	Trials
Innocrin Pharmaceutical	4
St Vincent's Hospital, Sydney	2
Prostate Cancer Foundation	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Other	4
Industry	4
NIH	1